

**Non Invasive Assessment of Hepatic Fibrosis
Regression in Hepatitis C Virus Infected Patients
Treated with Sofosbuvir Based Therapy**

Thesis

*Submitted for Partial Fulfillment of Master Degree in
Tropical Medicine*

By

Kerolous Boles Anwar Dous

M.B.B.ch

Faculty of Medicine-Sohag University

Under Supervision of

Prof. Ahmed Abbas Abdo EL-khattib

Professor of Tropical Medicine

Faculty of Medicine-Ain Shams University

Dr. Adham Mohamed Hamdan EL-Nakeeb

Head of Hepatology & Gastroenterology Department

Sohag Cardiology and Hepato-Gastroenterology Center

Dr. Heba Ismail Saad

Lecturer of Tropical Medicine

Faculty of Medicine-Ain Shams University

*Faculty of Medicine
Ain Shams University*

2019

Acknowledgment

*First and foremost, I feel always indebted to **God**,
the Most Kind and Most Merciful.*

*I'd like to express my respectful thanks and
profound gratitude to **Prof. Ahmed Abbas
Abdo El-khattib**, Professor of Tropical
Medicine, Faculty of Medicine-Ain Shams
University for his keen guidance, kind supervision,
valuable advice and continuous encouragement,
which made possible the completion of this work.*

*I am also delighted to express my deepest
gratitude and thanks to **Dr. Adham Mohamed
Hamdan El-Makeeb**, Head of Hepatology &
Gastroenterology Department Sohag Cardiology
and Hepato-Gastroenterology Center, for his kind
care, continuous supervision, valuable instructions,
constant help and great assistance throughout this
work.*

*I am deeply thankful to **Dr. Heba Ismail
Saad**, Lecturer of Tropical Medicine, Faculty of
Medicine-Ain Shams University, for her great help,
active participation and guidance.*

*I would like to express my hearty thanks to all
my family for their support till this work was
completed.*

*Last but not least my sincere thanks and
appreciation to all patients participated in this
study.*

Kerolous Boles

List of Contents

Title	Page No.
List of Tables	i
List of Figures	iii
List of Abbreviations	v
Introduction	1
Aim of the Work.....	15
Review of Literature	
☞ Hepatitis C Virus (HCV).....	16
☞ Liver Fibrosis	39
☞ HCV Antiviral Therapy	115
Patients and Methods	140
Results	147
Discussion	165
Conclusions	173
Recommendations	174
Summary	175
References	179
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Risk Factors for Developing Chronic HCV Infection	29
Table (2):	Risk Factors for Advanced Progression of Liver Fibrosis	33
Table (3):	Lesions considered in formulating the grading and staging systems	57
Table (4):	Knodell score (histology activity index score) of liver biopsy specimens for necrosis, inflammation, and fibrosis.....	60
Table (5):	METAVIR fibrosis and activity score	62
Table (6):	Ishak staging: Architectural changes, fibrosis, cirrhosis	63
Table (7):	Ishak score (modified Knodell score)	64
Table (8):	Characteristics of an ideal marker of liver fibrosis	66
Table (9):	Fibrosis markers	68
Table (10):	The correlation of direct serum markers with the histological substrate	72
Table (11):	Demographic data of studied patients	147
Table (12):	Baseline laboratory investigations.....	148
Table (13):	Baseline abdominal ultrasonography.....	149
Table (14):	Baseline Liver stiffness stages by Shear Wave Elastography (SWE)	150
Table (15):	Baseline liver stiffness of mean values by Shear Wave Elastography (SWE)	151
Table (16):	Baseline Serum markers of fibrosis.....	152

List of Tables (Cont...)

Table No.	Title	Page No.
Table (17):	Laboratory investigations during treatment.....	153
Table (18):	Serum markers of fibrosis during treatment.....	154
Table (19):	Laboratory investigation results 3 and 6 months after treatment	155
Table (20):	Liver stiffness stages 3 and 6 months after treatment	156
Table (21):	Liver stiffness mean values 3 and 6 months after treatment.....	157
Table (22):	Serum markers of fibrosis 3 and 6 months after treatment	157
Table (23):	Comparison between baseline vs. 3 months and baseline vs. 6 months after treatment regarding liver function tests and liver enzymes.....	158
Table (24):	Comparison between baseline vs. 3 months and baseline vs. 6 months after treatment regarding complete blood count	161
Table (25):	Comparison of liver stiffness stages between baseline, 3 months and 6 months after treatment	162
Table (26):	Comparison of liver stiffness mean values between baseline, 3 months and 6 months after treatment	163
Table (27):	Comparison of serum markers of fibrosis (Fib 4 and APRI) between baseline, 3 months and 6 months after treatment	164

List of Figures

Fig. No.	Title	Page No.
Figure (1):	Hepatitis C virus (HCV) structure	17
Figure (2):	Risk Factors and Modes of Transmission of HCV	21
Figure (3):	Natural History of HCV Infection	35
Figure (4):	Laboratory Markers with Acute Hepatitis C Infection	38
Figure (5):	Matrix and cellular alterations in hepatic fibrosis	42
Figure (6):	Diagram shows the various elastographic techniques	95
Figure (7):	pSWE: SIEMENS Acuson S2000.....	101
Figure (8):	Screen image of Philips iU22 in Elasto mode.	101
Figure (9):	The HCV life cycle and points of intervention	118
Figure (10):	Hepatitis C virus genome and potential drug discovery targets	119
Figure (11):	RBV mechanisms of action.....	136
Figure (12):	Show baseline Liver stiffness stages by Shear Wave Elastography (SWE).....	150
Figure (13):	Show baseline mean values of serum markers of fibrosis.....	152
Figure (14):	Show mean values of liver stiffness distribution 3 and 6 months after treatment...	156
Figure (15):	Show comparison of AST between baseline vs 3 months and baseline vs 6 months after treatment.....	159

List of Figures (Cont...)

Fig. No.	Title	Page No.
Figure (16):	Show comparison of ALT between baseline vs 3 months and baseline vs 6 months after treatment.....	159
Figure (17):	Show comparison of total bilirubin between baseline vs 3 months and baseline vs 6 months after treatment.....	160
Figure (18):	Show comparison of liver stiffness stages between baseline, 3 months and 6 months after treatment.....	162
Figure (19):	Show comparison of liver stiffness mean values mean values between baseline, 3 months and 6 months after treatment.	163
Figure (20):	Show serum markers of fibrosis (Fib 4 and APRI) between baseline, 3 months and 6 months after treatment.....	164

List of Abbreviations

Abb.	Full term
<i>AASLD</i>	<i>American Association for the Study of Liver Diseases</i>
<i>Ab</i>	<i>Antibody</i>
<i>AFP</i>	<i>Alpha feto protein</i>
<i>AIH</i>	<i>Autoimmune Hepatitis</i>
<i>ALB</i>	<i>Serum albumin</i>
<i>ALD</i>	<i>Alcoholic liver disease</i>
<i>ALP</i>	<i>Alkaline phosphatase</i>
<i>ALT</i>	<i>Alanine Aminotransferase</i>
<i>Apo A1</i>	<i>Apolipoprotein A1</i>
<i>APRI</i>	<i>Aspartate Aminotransferase-Platelet Ratio Index</i>
<i>APRI</i>	<i>AST to Platelet Ratio Index</i>
<i>ARFI</i>	<i>Acoustic Radiation Force Impulse Imaging</i>
<i>AST</i>	<i>Aspartate Aminotransferase</i>
<i>BCRP</i>	<i>Breast cancer resistance protein</i>
<i>BMI</i>	<i>Body Mass Index</i>
<i>BOC</i>	<i>Boceprevir</i>
<i>CBC</i>	<i>Complete blood count</i>
<i>CHB</i>	<i>Chronic Hepatitis B</i>
<i>CHC</i>	<i>Chronic Hepatitis C</i>
<i>CrkII</i>	<i>C10 regulator of kinase II</i>
<i>CT</i>	<i>Computed Tomography</i>
<i>CTLs</i>	<i>Cytotoxic T Lymphocytes</i>
<i>CTP</i>	<i>Child-Turcotte Pugh</i>
<i>DAAAs</i>	<i>Direct-acting antiviral agents</i>
<i>DCs</i>	<i>Dendritic Cells</i>
<i>DCV</i>	<i>Daclatasvir</i>
<i>DSV</i>	<i>Dasabuvir</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>EASL</i>	<i>European Association for Study of Liver</i>
<i>ECM</i>	<i>Extracellular Matrix</i>
<i>FDA</i>	<i>Food and Drug Administration</i>
<i>FFAs</i>	<i>Free Fatty Acids</i>
<i>FIB-4</i>	<i>Fibrosis-4 Score</i>
<i>FIB-4</i>	<i>The Fibrosis 4 index</i>
<i>GMBF</i>	<i>Gastric Mucosal Blood Flow</i>
<i>GT1</i>	<i>Genotype 1</i>
<i>GUCI</i>	<i>Göteborg University Cirrhosis Index</i>
<i>HA</i>	<i>Hyaluronic Acid</i>
<i>Hap</i>	<i>Haptoglobin</i>
<i>HB</i>	<i>Haemoglobin</i>
<i>HBsAg</i>	<i>Hepatitis B surface antigen</i>
<i>HCC</i>	<i>Hepatocellular Carcinoma</i>
<i>HCV</i>	<i>Hepatitis C virus</i>
<i>HSCs</i>	<i>Hepatic Stellate Cells</i>
<i>HVTT</i>	<i>Hepatic Vein Transit Times</i>
<i>ICC</i>	<i>Intraclass Correlation Coefficient</i>
<i>IDSA</i>	<i>Infectious Diseases Society of America</i>
<i>IFN</i>	<i>Interferon</i>
<i>IFNα</i>	<i>Interferon Alpha</i>
<i>IMPDH</i>	<i>Inhibition inosine 5'-monophosphate dehydrogenase</i>
<i>INR</i>	<i>International normalized ratio of prothrombin</i>
<i>IQR</i>	<i>Interquartile Range Interval</i>
<i>IR</i>	<i>Insulin Resistance</i>
<i>IUs</i>	<i>International Units</i>
<i>LDV</i>	<i>Ledipasvir</i>
<i>LS</i>	<i>Liver Stiffness</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>LSM</i>	<i>Liver stiffness measurements</i>
<i>LT</i>	<i>Liver Transplantation</i>
<i>MFs</i>	<i>Myofibroblasts</i>
<i>MMP</i>	<i>Matrix Metalloproteinase</i>
<i>MRE</i>	<i>Magnetic Resonance Elastography</i>
<i>MRI</i>	<i>Magnetic Resonance Imaging</i>
<i>MRP2</i>	<i>Multidrug resistance-associated protein 2</i>
<i>MTL - MMP</i>	<i>Membrane Type Matrix Metalloproteinase-L</i>
<i>mTOR</i>	<i>Mechanistic target of rapamycin</i>
<i>MTP</i>	<i>Microsomal Triglyceride Transfer Protein</i>
<i>NAAT</i>	<i>Nucleic Acid Amplification Test</i>
<i>NAFLD</i>	<i>Non-alcoholic fatty liver disease</i>
<i>NASH</i>	<i>Non-Alcoholic Steatohepatitis</i>
<i>NAT</i>	<i>Nucleic Acid Test</i>
<i>NCCVH</i>	<i>National Committee for the Control of Viral Hepatitis</i>
<i>NNPIs</i>	<i>Non-Nucleotide Polymerase Inhibitors</i>
<i>NPIs</i>	<i>Nucleotide/ Nucleoside Polymerase Inhibitors</i>
<i>NPV</i>	<i>Negative Predictive Value</i>
<i>NS3/4A</i>	<i>Nonstructural proteins 3/4A</i>
<i>NS5B</i>	<i>Nonstructural protein 5B</i>
<i>OATP</i>	<i>Organic anion transporting polypeptide</i>
<i>OBV</i>	<i>Ombitasvir</i>
<i>PBC</i>	<i>Primary Biliary Cholangitis</i>
<i>PCR</i>	<i>Polymerase chain reaction</i>
<i>PFV</i>	<i>Portal Flow Velocity</i>
<i>P-gp</i>	<i>P-glycoprotein</i>
<i>PI</i>	<i>Protease Inhibitors</i>
<i>PICP</i>	<i>Procollagen Type I Carboxy Terminal Peptide</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>PIIINP</i>	<i>Procollagen Type III Amino-Terminal Peptide</i>
<i>PLT</i>	<i>Platelet</i>
<i>PPAR-α</i>	<i>Peroxisome Proliferator-Activated Receptor Alpha</i>
<i>PSC</i>	<i>Primary Sclerosing Cholangitis</i>
<i>pSWE</i>	<i>Point Shear-Wave Elastography</i>
<i>PTV/r</i>	<i>Paritaprevir / Ritonavir</i>
<i>PVBF</i>	<i>Portal Venous Blood Flow</i>
<i>PVC</i>	<i>Polyvinylchloride</i>
<i>RASs</i>	<i>Resistance-Associated Substitutions</i>
<i>RBV</i>	<i>Ribavirin</i>
<i>RNA</i>	<i>Ribonucleic Acid</i>
<i>ROC</i>	<i>Receiver Operating Characteristic Curve</i>
<i>ROI</i>	<i>Region of Interest</i>
<i>ROS</i>	<i>Reactive Oxygen Species</i>
<i>SIM</i>	<i>Simeprevir</i>
<i>SOC</i>	<i>Standard of Care</i>
<i>SOCs</i>	<i>Suppressor of Cytokine Signaling</i>
<i>SOF</i>	<i>Sofosbuvir</i>
<i>SR</i>	<i>Success Rate</i>
<i>SS</i>	<i>Spleen Stiffness</i>
<i>SVR</i>	<i>Sustained Virological Response</i>
<i>SWV</i>	<i>Shear Wave Velocity</i>
<i>T.Bil</i>	<i>Total bilirubin</i>
<i>TCR</i>	<i>T-cell receptor</i>
<i>TE</i>	<i>Transient Elastography</i>
<i>TGF-β1</i>	<i>Transforming Growth Factor-β1</i>
<i>TIMPs</i>	<i>Tissue Inhibitors of Metallo-Proteinases</i>
<i>TLV</i>	<i>Telaprevir</i>

List of Abbreviations (Cont...)

Abb.	Full term
<i>TNF-α</i>	<i>Tumor Necrosis Factor Alpha</i>
<i>USA</i>	<i>United State of America</i>
<i>VAP</i>	<i>Velpatasvir</i>
<i>VLDL</i>	<i>Very Low Density Lipoprotein</i>
<i>VTQ</i>	<i>Virtual TouchTM Quantification</i>
<i>WBCs</i>	<i>White blood cells</i>
<i>WHO</i>	<i>World Health Organization</i>
<i>γGT</i>	<i>Gamma Glutamyl Transferase</i>

ABSTRACT

Background: Hepatitis C virus (HCV) is a major health problem worldwide. Its long-term impact ranges from minimal damage to extensive fibrosis and cirrhosis, which is sometimes, accompanied by hepatocellular carcinoma (HCC).

Aim of the Work: To evaluate early changes of hepatic fibrosis-related parameters in patients with chronic HCV patients using liver stiffness measurement using Shear wave elastography (Siemens-Acuson S2000) and serum parameters as APRI, FIB4 before and after sofosbuvir-based antiviral therapy.

Patients and Methods: This study were conducted on 109 Egyptian patients with chronic hepatitis C who were collected from viral hepatitis treatment unit in Sohag Cardiology and Hepato-Gastroenterology Center and followed up in the period between July 2017 and September 2018.

Results: The mean age of the studied patients was 45.76 ± 13.91 years, 67 (61.50%) of them were males while 42 (38.50%) were females. A history of diabetes was reported in 8 (7.30%) patients, 11 (10.10%) of our patients were hypertensive while 3 (2.80%) patients were ischemic heart disease. A total of 109 HCV-infected patients treated with sofosbuvir based therapy for 12 weeks were identified, 84 (77.10%) were treated with sofosbuvir 400 mg/day and daclatasvir 60 mg/day and 25 (22.90%) were treated with sofosbuvir 400 mg/day and daclatasvir 60 mg/day with weight-based ribavirin (1000 mg { below 75 kg} to 1200 mg {above 75mg}).

Conclusion: Sofosbuvir-based treatment regimens for CHC result in significant reduction in Liver stiffness measurements (LSM) by pSWE with significant changes in the distribution of patients among the fibrosis stages except liver fibrosis stage 4 (F4) and significant improvement in fibrosis scores (FIB4 and APRI) 24 weeks post treatment.

Keywords: *Sofosbuvir - Hepatitis C Virus - Hepatic Fibrosis Regression*

INTRODUCTION

Hepatitis C virus (HCV) is a major health problem worldwide. Its long-term impact ranges from minimal damage to extensive fibrosis and cirrhosis, which is sometimes, accompanied by hepatocellular carcinoma (HCC) (*EASL, 2014*).

In 2015, the global prevalence of HCV infection was 1.0%, with the highest prevalence in the Eastern Mediterranean Region (2.3%) followed by the European one (1.5%). The annual mortality due to HCV related complications is estimated to be approximately 700000 deaths (*WHO, 2016*).

The objective of chronic hepatitis C (CHC) treatment is to achieve a sustained virological response (SVR), defined as the absence of viral replication 12 or 24 weeks after treatment completion. A SVR which is stable over time, reduces morbidity and mortality, and is considered in most cases to be equivalent to cured HCV infection (*van der Meer, 2012*).

Liver fibrosis is the main determinant of hepatitis C virus–related morbidity and mortality (*Poynard et al., 1997*). In addition, the stage of fibrosis is prognostic and provides information on the likelihood of disease progression and response to treatment (*Marcellin et al., 2002*).

Liver biopsy is currently the gold standard for staging fibrosis, but it has well-documented complications of pain, bleeding, and rarely, death (*Bravo et al., 2001*). Liver biopsy is

also expensive, as are the costs associated with treating its complications. In addition, inter- and intra-observer error may lead to incorrect staging (*Marcellin et al., 2002*), as may sampling error in up to 33% of biopsies (*Regev et al., 2002*).

More recently, clinical investigators have been searching for noninvasive serum markers of fibrosis (*Afdhal, 2003*). These can be individual markers or a series of markers from which a fibrosis index can be derived. In either case, these marker tests must have the following characteristics: they must be reliable, accurate, reproducible, and easy to perform. In addition, they must reflect total mass of liver collagen and extracellular matrix (ECM) and be able to reflect both fibrogenesis and fibrosis regression. The ideal marker test would be able to accurately stage disease and also be sensitive to changes in fibrosis induced by therapy or the natural history of disease progression (*Afdhal, 2004*).

No single marker fulfill all of the proposed criteria to merit routine clinical use. A combination of markers including those that reflect alterations in hepatic synthetic function and markers of extracellular matrix turnover are emerging as useful diagnostic tests for differentiating early from advanced cirrhosis (*Thabut et al., 2003*).

Noninvasive approach to assessment of severity of hepatitis C include clinical symptoms and signs, routine biochemical and hematologic blood tests, serum markers of fibrosis and inflammation, combinations of clinical and blood